Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis

Abstract Background Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. However, there are no head-to-head trials comparing the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Takeshi Nakahara, Hiroyuki Murota, Miyuki Matsukawa, Hiroe Takeda, Yilong Zhang, Tomohiro Kondo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2024-10-01
Edice:	Dermatology and Therapy
Témata:	Atopic dermatitis Delgocitinib Difamilast EASI MAIC
On-line přístup:	https://doi.org/10.1007/s13555-024-01282-1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!